140 related articles for article (PubMed ID: 38554212)
21. Tissue Proteogenomic Landscape Reveals the Role of Uncharacterized SEL1L3 in Progression and Immunotherapy Response in Lung Adenocarcinoma.
Shen CY; Chang WH; Chen YJ; Weng CW; Regmi P; Kier MKK; Su KY; Chang GC; Chen JS; Chen YJ; Yu SL
J Proteome Res; 2023 Apr; 22(4):1056-1070. PubMed ID: 36349894
[TBL] [Abstract][Full Text] [Related]
22. CT-based radiomics in predicting pathological response in non-small cell lung cancer patients receiving neoadjuvant immunotherapy.
Lin Q; Wu HJ; Song QS; Tang YK
Front Oncol; 2022; 12():937277. PubMed ID: 36267975
[TBL] [Abstract][Full Text] [Related]
23. Machine learning on syngeneic mouse tumor profiles to model clinical immunotherapy response.
Zeng Z; Gu SS; Wong CJ; Yang L; Ouardaoui N; Li D; Zhang W; Brown M; Liu XS
Sci Adv; 2022 Oct; 8(41):eabm8564. PubMed ID: 36240281
[TBL] [Abstract][Full Text] [Related]
24. Spatially resolved proteomic profiling identifies tumor cell CD44 as a biomarker associated with sensitivity to PD-1 axis blockade in advanced non-small-cell lung cancer.
Moutafi MK; Molero M; Martinez Morilla S; Baena J; Vathiotis IA; Gavrielatou N; Castro-Labrador L; de Garibay GR; Adradas V; Orive D; Valencia K; Calvo A; Montuenga LM; Ponce Aix S; Schalper KA; Herbst RS; Paz-Ares L; Rimm DL; Zugazagoitia J
J Immunother Cancer; 2022 Aug; 10(8):. PubMed ID: 36002182
[TBL] [Abstract][Full Text] [Related]
25. Atezolizumab versus chemotherapy in advanced or metastatic NSCLC with high blood-based tumor mutational burden: primary analysis of BFAST cohort C randomized phase 3 trial.
Peters S; Dziadziuszko R; Morabito A; Felip E; Gadgeel SM; Cheema P; Cobo M; Andric Z; Barrios CH; Yamaguchi M; Dansin E; Danchaivijitr P; Johnson M; Novello S; Mathisen MS; Shagan SM; Schleifman E; Wang J; Yan M; Mocci S; Voong D; Fabrizio DA; Shames DS; Riehl T; Gandara DR; Mok T
Nat Med; 2022 Sep; 28(9):1831-1839. PubMed ID: 35995953
[TBL] [Abstract][Full Text] [Related]
26. Assessing the robustness of radiomics/deep learning approach in the identification of efficacy of anti-PD-1 treatment in advanced or metastatic non-small cell lung carcinoma patients.
Ren Q; Xiong F; Zhu P; Chang X; Wang G; He N; Jin Q
Front Oncol; 2022; 12():952749. PubMed ID: 35992867
[TBL] [Abstract][Full Text] [Related]
27. Dissecting the clinicopathologic, genomic, and immunophenotypic correlates of KRAS
Ricciuti B; Alessi JV; Elkrief A; Wang X; Cortellini A; Li YY; Vaz VR; Gupta H; Pecci F; Barrichello A; Lamberti G; Nguyen T; Lindsay J; Sharma B; Felt K; Rodig SJ; Nishino M; Sholl LM; Barbie DA; Negrao MV; Zhang J; Cherniack AD; Heymach JV; Meyerson M; Ambrogio C; Jänne PA; Arbour KC; Pinato DJ; Skoulidis F; Schoenfeld AJ; Awad MM; Luo J
Ann Oncol; 2022 Oct; 33(10):1029-1040. PubMed ID: 35872166
[TBL] [Abstract][Full Text] [Related]
28. Artificial intelligence-derived gut microbiome as a predictive biomarker for therapeutic response to immunotherapy in lung cancer: protocol for a multicentre, prospective, observational study.
Shoji F; Yamashita T; Kinoshita F; Takamori S; Fujishita T; Toyozawa R; Ito K; Yamazaki K; Nakashima N; Okamoto T
BMJ Open; 2022 Jun; 12(6):e061674. PubMed ID: 35676015
[TBL] [Abstract][Full Text] [Related]
29. Deep learning for predicting immunotherapeutic efficacy in advanced non-small cell lung cancer patients: a retrospective study combining progression-free survival risk and overall survival risk.
He BX; Zhong YF; Zhu YB; Deng JJ; Fang MJ; She YL; Wang TT; Yang Y; Sun XW; Belluomini L; Watanabe S; Dong D; Tian J; Xie D
Transl Lung Cancer Res; 2022 Apr; 11(4):670-685. PubMed ID: 35529789
[TBL] [Abstract][Full Text] [Related]
30. First-line immunotherapy or angiogenesis inhibitor plus chemotherapy for
Yang G; Yang Y; Liu R; Li W; Xu H; Hao X; Li J; Xing P; Zhang S; Ai X; Xu F; Wang Y
Ther Adv Med Oncol; 2022; 14():17588359221082339. PubMed ID: 35251321
[TBL] [Abstract][Full Text] [Related]
31. Personalized circulating tumor DNA analysis as a predictive biomarker in solid tumor patients treated with pembrolizumab.
Bratman SV; Yang SYC; Iafolla MAJ; Liu Z; Hansen AR; Bedard PL; Lheureux S; Spreafico A; Razak AA; Shchegrova S; Louie M; Billings P; Zimmermann B; Sethi H; Aleshin A; Torti D; Marsh K; Eagles J; Cirlan I; Hanna Y; Clouthier DL; Lien SC; Ohashi PS; Xu W; Siu LL; Pugh TJ
Nat Cancer; 2020 Sep; 1(9):873-881. PubMed ID: 35121950
[TBL] [Abstract][Full Text] [Related]
32. Exploring Response to Immunotherapy in Non-Small Cell Lung Cancer Using Delta-Radiomics.
Barabino E; Rossi G; Pamparino S; Fiannacca M; Caprioli S; Fedeli A; Zullo L; Vagge S; Cittadini G; Genova C
Cancers (Basel); 2022 Jan; 14(2):. PubMed ID: 35053513
[TBL] [Abstract][Full Text] [Related]
33. Immune biomarkers and response to checkpoint inhibition of BRAF
Murciano-Goroff YR; Pak T; Mondaca S; Flynn JR; Montecalvo J; Rekhtman N; Halpenny D; Plodkowski AJ; Wu SL; Kris MG; Paik PK; Riely GJ; Yu HA; Rudin CM; Hellmann MD; Land JD; Buie LW; Heller G; Lito P; Yaeger R; Drilon A; Liu D; Li BT; Offin M
Br J Cancer; 2022 Apr; 126(6):889-898. PubMed ID: 34963703
[TBL] [Abstract][Full Text] [Related]
34. Relationship of the lung microbiome with PD-L1 expression and immunotherapy response in lung cancer.
Jang HJ; Choi JY; Kim K; Yong SH; Kim YW; Kim SY; Kim EY; Jung JY; Kang YA; Park MS; Kim YS; Cho YJ; Lee SH
Respir Res; 2021 Dec; 22(1):322. PubMed ID: 34963470
[TBL] [Abstract][Full Text] [Related]
35. Predicting heterogeneity in clone-specific therapeutic vulnerabilities using single-cell transcriptomic signatures.
Suphavilai C; Chia S; Sharma A; Tu L; Da Silva RP; Mongia A; DasGupta R; Nagarajan N
Genome Med; 2021 Dec; 13(1):189. PubMed ID: 34915921
[TBL] [Abstract][Full Text] [Related]
36. Local tumor microbial signatures and response to checkpoint blockade in non-small cell lung cancer.
Boesch M; Baty F; Albrich WC; Flatz L; Rodriguez R; Rothschild SI; Joerger M; Früh M; Brutsche MH
Oncoimmunology; 2021; 10(1):1988403. PubMed ID: 34912592
[TBL] [Abstract][Full Text] [Related]
37. A Novel Adaptive Fuzzy Deep Learning Approach for Histopathologic Cancer Detection.
Yan X; Ding J; Cheng HD
Annu Int Conf IEEE Eng Med Biol Soc; 2021 Nov; 2021():3518-3521. PubMed ID: 34891998
[TBL] [Abstract][Full Text] [Related]
38. Real-world performance of blood-based proteomic profiling in first-line immunotherapy treatment in advanced stage non-small cell lung cancer.
Rich P; Mitchell RB; Schaefer E; Walker PR; Dubay JW; Boyd J; Oubre D; Page R; Khalil M; Sinha S; Boniol S; Halawani H; Santos ES; Brenner W; Orsini JM; Pauli E; Goldberg J; Veatch A; Haut M; Ghabach B; Bidyasar S; Quejada M; Khan W; Huang K; Traylor L; Akerley W
J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34706885
[TBL] [Abstract][Full Text] [Related]
39. Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer.
Negrao MV; Skoulidis F; Montesion M; Schulze K; Bara I; Shen V; Xu H; Hu S; Sui D; Elamin YY; Le X; Goldberg ME; Murugesan K; Wu CJ; Zhang J; Barreto DS; Robichaux JP; Reuben A; Cascone T; Gay CM; Mitchell KG; Hong L; Rinsurongkawong W; Roth JA; Swisher SG; Lee J; Tsao A; Papadimitrakopoulou V; Gibbons DL; Glisson BS; Singal G; Miller VA; Alexander B; Frampton G; Albacker LA; Shames D; Zhang J; Heymach JV
J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34376553
[TBL] [Abstract][Full Text] [Related]
40. IMpower150 Final Overall Survival Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in First-Line Metastatic Nonsquamous NSCLC.
Socinski MA; Nishio M; Jotte RM; Cappuzzo F; Orlandi F; Stroyakovskiy D; Nogami N; Rodríguez-Abreu D; Moro-Sibilot D; Thomas CA; Barlesi F; Finley G; Kong S; Lee A; Coleman S; Zou W; McCleland M; Shankar G; Reck M
J Thorac Oncol; 2021 Nov; 16(11):1909-1924. PubMed ID: 34311108
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
